drugset
drugset / Trial / NCT05721573

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

NCT05721573 ↗

Phase 2/3 Completed 272 enrolled Abcuro, Inc. Syneos Health · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Timeline

Start
2023-02-28
Primary completion
2025-11-06
Completion
2025-11-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ulviprubart Monoclonal antibody 0.5 mg/kg Subcutaneous
Comparator Ulviprubart Monoclonal antibody 2 mg/kg Subcutaneous

Indications

inclusion body myositis